Equities

China Traditional Chinese Medicine Holdings Co Ltd

China Traditional Chinese Medicine Holdings Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)4.27
  • Today's Change-0.03 / -0.70%
  • Shares traded38.70m
  • 1 Year change-0.23%
  • Beta0.6457
Data delayed at least 15 minutes, as of Apr 30 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

China Traditional Chinese Medicine Holdings Co. Limited is principally engaged in the manufacture and sales of traditional Chinese medicine (TCM). The Company operates through 12 subsidiaries, including Sinopharm Group Dezhong (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Pharmaceutical Co., Ltd., Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd., Sinopharm Group Luya (Shandong) Pharmaceutical Co., Ltd., Sinopharm Group Feng Liao Xing (Foshan) Medicinal Material & Slices Co., Ltd., Foshan Winteam Pharmaceutical Sales Company Limited, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Sinopharm Group Jingfang (Anhui) Pharmaceutical Co., Ltd., Sinopharm Group Longlife (Guizhou) Pharmaceutical Co., Ltd., Qinghai Pulante Pharmaceutical Co., Ltd., Guizhou Zhongtai Biological Technology Company Limited and its subsidiaries and Jiangyin Tianjiang Pharmaceutical Co., Ltd. and its subsidiaries.

  • Revenue in HKD (TTM)19.58bn
  • Net income in HKD1.39bn
  • Incorporated1992
  • Employees17.30k
  • Location
    China Traditional Chinese Medicine Holdings Co LtdRoom 1601, Emperor Group Centre288 Hennessy RoadWanchai Hong KongHKG
  • Phone+852 28543393
  • Fax+852 25441269
  • Websitehttps://www.china-tcm.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SciClone Pharmaceuticals (Holdings) Ltd3.41bn1.21bn11.30bn1.05k9.673.2014.773.311.861.865.245.630.75853.563.833,246,682.0026.9727.0933.3436.3274.6776.0635.5535.434.5027.950.01--14.7617.5031.1615.96----
Yichang Hec Changjiang Pharmactcl Co Ltd6.80bn2.15bn11.51bn4.62k5.351.344.741.692.452.457.739.740.51113.624.001,472,510.0015.078.0324.4611.8179.2179.9729.4820.801.309.320.2475--68.0820.182,501.2416.15----
Zai Lab Ltd2.09bn-2.62bn12.46bn2.18k--1.96--5.97-2.71-2.712.166.410.23642.515.38---29.66-37.72-34.97-42.7264.0864.75-125.46-282.444.41--0.00--24.03360.0324.51---3.45--
Simcere Pharmaceutical Group Ltd7.14bn772.16m14.09bn7.03k18.641.8112.751.970.28970.28972.742.980.61063.532.651,015,857.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
SSY Group Ltd6.46bn1.32bn14.16bn5.60k10.782.048.102.190.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
3SBio Inc8.44bn1.67bn15.12bn5.41k9.190.98097.291.790.67450.67453.466.320.34261.586.751,560,446.006.957.449.039.2984.9882.9120.3021.502.265.260.2266--13.8411.26-19.133.94----
Grand Pharmaceutical Group Ltd10.53bn1.88bn15.44bn10.53k8.121.006.751.470.53560.53563.004.330.46922.945.06999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981923.210.183126.9510.1212.06-9.5921.41--24.77
The United Laboratories Intl. Hldgs Ltd.14.84bn2.92bn16.73bn15.00k5.731.224.741.131.611.618.177.570.68713.363.26989,547.9013.517.8920.5212.6446.1144.1719.6612.731.74--0.105515.5121.2212.8470.8531.66--14.67
China Traditional Chinese Med Hldg CoLtd19.58bn1.39bn21.65bn17.30k15.600.94738.021.110.27570.27573.894.540.49861.472.091,131,427.003.844.605.857.0751.1857.077.709.771.488.010.1773--26.699.9968.11-2.24----
Genscript Biotech Corp6.57bn-747.42m24.98bn6.94k--2.29--3.80-0.3548-0.35483.125.140.2837.595.45947,395.80-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
WuXi XDC Cayman Inc2.29bn306.31m26.23bn1.18k84.264.3869.6811.430.25990.25991.955.00------1,947,697.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
RemeGen Co Ltd1.16bn-1.63bn26.94bn3.62k--4.03--23.17-3.03-3.032.166.900.18640.40054.31321,589.30-26.17-18.66-31.75-23.7576.4881.94-140.43-102.881.31-64.320.2682--40.16148.65-51.30--59.07--
HUTCHMED (China) Ltd6.56bn788.94m27.01bn1.99k34.464.7231.574.120.89950.89957.636.560.72587.197.693,299,853.008.76-14.3513.36-20.4354.1236.5712.06-31.442.60--0.1038--96.5231.38127.93--38.65--
Data as of Apr 30 2024. Currency figures normalised to China Traditional Chinese Medicine Holdings Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

18.04%Per cent of shares held by top holders
HolderShares% Held
Ping An of China Asset Management (Hong Kong) Co., Ltd.as of 30 Jun 2023604.30m12.00%
The Vanguard Group, Inc.as of 05 Apr 202492.78m1.84%
Dimensional Fund Advisors LPas of 04 Apr 202466.60m1.32%
BlackRock Fund Advisorsas of 04 Apr 202432.43m0.64%
Bosera Asset Management Co., Ltd.as of 31 Dec 202227.48m0.55%
First Seafront Fund Management Co., Ltd.as of 30 Jun 202324.26m0.48%
HuaAn Fund Management Co., Ltd.as of 30 Jun 202320.21m0.40%
Yinhua Fund Management Co., Ltd.as of 30 Jun 202314.98m0.30%
Geode Capital Management LLCas of 29 Feb 202413.03m0.26%
Bankinter Gesti�n de Activos SA SGIICas of 30 Jun 202312.32m0.25%
More ▼
Data from 30 Jun 2023 - 22 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.